AGC Biologics To Build New Mfg Facility in Japan
AGC Biologics, a Bothell, Washington-headquartered contract development and manufacturing organization of biologics, plans to establish a new process development and manufacturing facility at its facility in Chiba, Japan. This move is part of the company’s ongoing program to expand its production capacities globally.
The new facility, which is expected to be operational in the second half of 2019, will contain single-use bioreactors at the 500- and 2,000-liter scale and will be suited for producing monoclonal antibodies, fusion proteins, and other types of therapeutic proteins.
AGC Biologics currently provides mammalian protein process development and manufacturing services from its facilities in Bothell, Washington, Berkeley, California and Copenhagen, Denmark as well as microbial process development and manufacturing services from its facilities in Heidelberg, Germany, Copenhagen Denmark, and Chiba Japan.
Source: AGC Biologics